摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Indolo[2,3-b]carbazole | 241-35-0

中文名称
——
中文别名
——
英文名称
Indolo[2,3-b]carbazole
英文别名
——
Indolo[2,3-b]carbazole化学式
CAS
241-35-0
化学式
C18H10N2
mdl
——
分子量
254.3
InChiKey
HLYDAUPLQZMMTR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    526.5±50.0 °C(Predicted)
  • 密度:
    1.34±0.1 g/cm3(Predicted)
  • 熔点:
    358-360 °C

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    20
  • 可旋转键数:
    0
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    24.7
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • COMPOSITIONS FOR ELECTRONIC APPLICATIONS
    申请人:Feldman Jerals
    公开号:US20130248849A1
    公开(公告)日:2013-09-26
    This invention relates to a composition including (a) a dopant, (b) a first host having at least one unit of Formula I, and (c) a second host compound. Formula I has the structure where Q is a fused ring linkage having the formula In Formula I: R 1 is the same or different at each occurrence and is D, alkyl, aryl, silyl, alkoxy, aryloxy, cyano, vinyl, or allyl; R 2 is the same or different at each occurrence and is H, D, alkyl, or aryl, or both R 2 are an N-heterocycle; R 3 is the same or different at each occurrence and is H, D, cyano, alkyl or aryl; and a is the same or different at each occurrence and is an integer from 0-4.
    本发明涉及一种组合物,包括(a)掺杂剂,(b)至少具有一个I式单元的第一主体,以及(c)第二主体化合物。式I具有以下结构:其中Q是具有以下式的融合环链:在式I中:R1在每个出现的位置上相同或不同,是D,烷基,芳基,硅烷基,烷氧基,芳氧基,氰基,乙烯基或烯丙基;R2在每个出现的位置上相同或不同,是氢,D,烷基或芳基,或者两个R2均为N-杂环;R3在每个出现的位置上相同或不同,是氢,D,氰基,烷基或芳基;a在每个出现的位置上相同或不同,是0-4的整数。
  • Lipoxygenase inhibitors
    申请人:SRI International
    公开号:US10646471B2
    公开(公告)日:2020-05-12
    The disclosure provides bisindole suitable for inhibiting lipoxygenases or Aβ-formation, and treating associated diseases, such as Alzheimer's disease. The bisindoles are indolo[2,3-b]carbazole derivatives, and may be administered to a patient as part of a pharmaceutical formulation.
    本公开提供了适用于抑制脂氧合酶或 Aβ 形成以及治疗相关疾病(如阿尔茨海默病)的双吲哚。双吲哚是吲哚并[2,3-b]咔唑衍生物,可作为药物制剂的一部分施用给患者。
  • Hydrogen storage by reversible hydrogenation of pi-conjugated substrates
    申请人:Pez Peter Guido
    公开号:US20050002857A1
    公开(公告)日:2005-01-06
    Processes are provided for the storage and release of hydrogen by means of a substantially reversible catalytic hydrogenation of extended pi-conjugated substrates which include large polycyclic aromatic hydrocarbons, polycyclic aromatic hydrocarbons with nitrogen heteroatoms, polycyclic aromatic hydrocarbons with oxygen heteroatoms, polycyclic aromatic hydrocarbons with alkyl, alkoxy, nitrile, ketone, ether or polyether substituents, pi-conjugated molecules comprising 5 membered rings, pi-conjugated molecules comprising six and five membered rings with nitrogen or oxygen hetero atoms, and extended pi-conjugated organic polymers. The hydrogen, contained in the at least partially hydrogenated form of the extended pi-conjugated system, can be facilely released for use by a catalytic dehydrogenation of the latter in the presence of a dehydrogenation catalyst which can be effected by lowering the hydrogen gas pressure, generally to pressures greater than 0.1 bar or raising the temperature to less than 250° C. or less, or by a combination of these two process parameters.
    本发明提供了通过对扩展的π-共轭基质进行基本可逆的催化加氢来储存和释放氢气的工艺、具有烷基、烷氧基、腈基、酮基、醚基或聚醚基取代基的多环芳香烃,由 5 个成员环组成的π-共轭分子,由具有氮或氧杂质原子的 6 个和 5 个成员环组成的π-共轭分子,以及扩展的π-共轭有机聚合物。扩展π-共轭体系的至少部分氢化形式中含有的氢,可以在脱氢催化剂的存在下,通过催化脱氢反应方便地释放出来,脱氢反应可以通过降低氢气压力(一般压力大于 0.1 巴)或将温度升高到低于 250 摄氏度或更低,或通过这两种工艺参数的组合来实现。
  • Dehydrogenation of liquid fuel in microchannel catalytic reactor
    申请人:Toseland Allen Bernard
    公开号:US20060143981A1
    公开(公告)日:2006-07-06
    The present invention is an improved process for the storage and delivery of hydrogen by the reversible hydrogenation/dehydrogenation of an organic compound wherein the organic compound is initially in its hydrogenated state. The improvement in the route to generating hydrogen is in the dehydrogenation step and recovery of the dehydrogenated organic compound resides in the following steps: introducing a hydrogenated organic compound to a microchannel reactor incorporating a dehydrogenation catalyst; effecting dehydrogenation of said hydrogenated organic compound under conditions whereby said hydrogenated organic compound is present as a liquid phase; generating a reaction product comprised of a liquid phase dehydrogenated organic compound and gaseous hydrogen; separating the liquid phase dehydrogenated organic compound from gaseous hydrogen; and, recovering the hydrogen and liquid phase dehydrogenated organic compound.
    本发明是一种通过有机化合物的可逆氢化/脱氢来储存和输送氢气的改进工艺,其中有机化合物最初处于氢化状态。氢气生成路线的改进在于脱氢步骤和脱氢有机化合物的回收,具体步骤如下:将氢化有机化合物引入含有脱氢催化剂的微通道反应器;在所述氢化有机化合物以液相形式存在的条件下对所述氢化有机化合物进行脱氢;生成由液相脱氢有机化合物和气态氢组成的反应产物;将液相脱氢有机化合物与气态氢分离;以及回收氢和液相脱氢有机化合物。
  • TREATMENT OF FIBROMYALGIA AND RELATED DISORDERS
    申请人:Designed Nutritional Products Inc.
    公开号:EP1030663A1
    公开(公告)日:2000-08-30
查看更多

同类化合物

(Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (R)-(+)-5'-苄氧基卡维地洛 (R)-卡洛芬 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (3Z)-3-(1H-咪唑-5-基亚甲基)-5-甲氧基-1H-吲哚-2-酮 (3Z)-3-[[[4-(二甲基氨基)苯基]亚甲基]-1H-吲哚-2-酮 (3R)-(-)-3-(1-甲基吲哚-3-基)丁酸甲酯 (3-氯-4,5-二氢-1,2-恶唑-5-基)(1,3-二氧代-1,3-二氢-2H-异吲哚-2-基)乙酸 齐多美辛 鸭脚树叶碱 鸭脚木碱,鸡骨常山碱 鲜麦得新糖 高氯酸1,1’-二(十六烷基)-3,3,3’,3’-四甲基吲哚碳菁 马鲁司特 马来酸阿洛司琼 马来酸替加色罗 顺式-ent-他达拉非 顺式-1,3,4,4a,5,9b-六氢-2H-吡啶并[4,3-b]吲哚-2-甲酸乙酯 顺式-(+-)-3,4-二氢-8-氯-4'-甲基-4-(甲基氨基)-螺(苯并(cd)吲哚-5(1H),2'(5'H)-呋喃)-5'-酮 靛红联二甲酚 靛红磺酸钠 靛红磺酸 靛红乙烯硫代缩酮 靛红-7-甲酸甲酯 靛红-5-磺酸钠 靛红-5-磺酸 靛红-5-硫酸钠盐二水 靛红-5-甲酸甲酯 靛红 靛玉红3'-单肟5-磺酸 靛玉红-3'-单肟 靛玉红 青色素3联己酸染料,钾盐 雷马曲班 雷莫司琼杂质13 雷莫司琼杂质12 雷莫司琼杂质 雷替尼卜定 雄甾-1,4-二烯-3,17-二酮 阿霉素的代谢产物盐酸盐 阿贝卡尔 阿西美辛叔丁基酯 阿西美辛 阿莫曲普坦杂质1 阿莫曲普坦 阿莫曲坦二聚体杂质 阿莫曲坦 阿洛司琼杂质